ESR1 and breast carcinoma: Aromatase inhibitors (AIs) (e.g., letrozole, exemestane, and anastrozole) are commonly used HTs for postmenopausal women with ER/PR-positive breast cancer in adjuvant, neoadjuvant, or metastatic settings [88].